Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.
QU C.F.;
SONG E.;
LI Y.;
RIZVI S.M.A.;
RAJA C.;
ROSS R;
APOSTOLIDIS Christos;
ALLEN Barry J.;
MORGENSTERN Alfred;
2007-01-15
SPRINGER
JRC33606
https://publications.jrc.ec.europa.eu/repository/handle/JRC33606,
Additional supporting files
| File name | Description | File type | |
|---|
